Atrium Therapeutics, Inc. (RNA) Stock Forecast
Data as of Sep 21, 2026Healthcare · Current price $9.03 (-5.54%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
RNA vs Sector & Market
| Metric | RNA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.25 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +176.8% | +22243.5% | +21.5% |
| P/E Ratio | -2.80 | 3.76 | 38.34 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $5M | $5M | $5M | 1 |
| 2026-12-31 | $11M | $11M | $11M | 1 |
| 2027-12-31 | $149M | $288M | $438M | 4 |
| 2028-12-31 | $876M | $913M | $950M | 7 |
| 2029-12-31 | $862M | $1.61B | $2.54B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.34 | $-1.34 | $-1.34 | 1 |
| 2026-12-31 | $-1.34 | $-1.34 | $-1.34 | 1 |
| 2027-12-31 | $-4.05 | $-4.01 | $-3.95 | 3 |
| 2028-12-31 | $-4.48 | $-1.82 | $1.96 | 6 |
| 2029-12-31 | $0.73 | $1.83 | $3.21 | 4 |
Frequently Asked Questions
What is the analyst consensus for RNA?
The consensus among 1 analysts covering Atrium Therapeutics, Inc. (RNA) is Hold with an average price target of $25.00.
What is the highest price target for RNA?
The highest analyst price target for RNA is $25.00.
What is the lowest price target for RNA?
The lowest analyst price target for RNA is $25.00.
How many analysts cover RNA?
1 analysts have issued ratings for Atrium Therapeutics, Inc. in the past 12 months.
Is RNA a buy or sell right now?
Based on 1 analyst ratings, RNA has a consensus rating of Hold (3.00/5) with a +176.8% upside to the consensus target of $25.00.
What are the earnings estimates for RNA?
Analysts estimate RNA will report EPS of $-1.34 for the period ending 2026-09-30, with revenue estimated at $5M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.